SAFETY OF LONG-TERM USE OF BENZODIAZEPINES IN GERIATRIC PATIENTS – A REVIEW OF CURRENT EVIDENCE AND RECOMMENDATIONS
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.5859Keywords:
Benzodiazepines, Elderly, Geriatric Pharmacology, Falls, Delirium, Deprescribing, Cognitive ImpairmentAbstract
Background: Benzodiazepines remain frequently prescribed in older adults despite long-standing concerns regarding their safety. Age-related pharmacokinetic and pharmacodynamic changes, combined with increased sensitivity of the central nervous system, may amplify adverse effects. This narrative review aims to summarize current evidence on the risks associated with long-term benzodiazepine use in geriatric populations and to outline contemporary clinical recommendations for deprescribing.
Results: Long-term benzodiazepine use in older adults is consistently associated with an increased risk of adverse outcomes, particularly falls and fractures, impaired cognitive function, and delirium. Evidence regarding dementia risk remains inconclusive, with observational studies suggesting a possible association, though confounding by indication cannot be excluded. Concomitant use with opioids significantly increases the risk of respiratory depression and mortality. Major clinical guidelines, including Beers Criteria and STOPP/START criteria, strongly recommend avoiding benzodiazepines in older adults, except for specific short-term indications. Deprescribing strategies, including gradual dose tapering and substitution with non-pharmacological interventions such as cognitive behavioral therapy for insomnia (CBT-I), have demonstrated effectiveness in reducing long-term use.
Conclusions: Current evidence indicates that long-term benzodiazepine use in geriatric patients is associated with significant and potentially preventable harms. Despite this, inappropriate prescribing remains common in clinical practice. Structured deprescribing strategies and increased adherence to clinical guidelines are essential to improving patient safety in older populations.
References
American Geriatrics Society Beers Criteria® Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria®. J Am Geriatr Soc, 71(7), 2052–2081.
O’Mahony, D., O’Sullivan, D., Byrne, S., et al. (2023). STOPP/START criteria version 3. Age Ageing, 52(1), afac649.
National Institute for Health and Care Excellence (NICE). (2020). Generalised anxiety disorder and panic disorder (CG113). 2020 update.
National Institute for Health and Care Excellence (NICE). (n.d.). Insomnia management (CG66). Updated guidance.
U.S. Food and Drug Administration (FDA). (2016). Boxed warning: Opioid and benzodiazepine combination.
European Medicines Agency (EMA). (n.d.). Benzodiazepine safety and dependence warnings. PRAC reports.
Woolcott, J. C., Richardson, K. J., Wiens, M. O., et al. (2009). Meta-analysis of medications and falls. Arch Intern Med, 169, 1952–1960.
Donnelly, K., Bracchi, R., Hewitt, J., et al. (2017). Benzodiazepines and hip fracture risk. PLoS One, 12, e0174730.
Leipzig, R. M., Cumming, R. G., & Tinetti, M. E. (1999). Drugs and falls in older people: Systematic review. J Am Geriatr Soc, 47, 30–39.
Gray, S. L., Dublin, S., Yu, O., et al. (2016). Benzodiazepine use and dementia risk. BMJ, 352, i90.
Zhong, G., Wang, Y., Zhang, Y., & Zhao, Y. (2015). Benzodiazepines and dementia: Meta-analysis. PLoS One, 10, e0127836.
Billioti de Gage, S., Moride, Y., Ducruet, T., et al. (2014). Benzodiazepine use and Alzheimer’s disease. BMJ, 349, g5205.
Inouye, S. K., Westendorp, R. G. J., & Saczynski, J. S. (2014). Delirium in elderly people. N Engl J Med, 370, 1369–1377.
Pandharipande, P. P., Girard, T. D., Jackson, J. C., et al. (2013). Long-term cognitive impairment after ICU delirium. N Engl J Med, 369, 1306–1316.
Pottie, K., Thompson, W., Davies, S., et al. (2018). Deprescribing benzodiazepines guideline. Can Fam Physician, 64, 339–351.
Tannenbaum, C., Martin, P., Tamblyn, R., et al. (2014). Reduction of inappropriate benzodiazepine use. JAMA Intern Med, 174(6), 890–898.
Vicens, C., Bejarano, F., Sempere, E., et al. (2014). Withdrawal from long-term benzodiazepine use. Br J Gen Pract, 64, e563–e571.
Weich, S., Pearce, H. L., Croft, P., et al. (2014). Benzodiazepine use and mortality. BMJ, 348, g1996.
Kripke, D. F., Langer, R. D., & Kline, L. E. (2012). Hypnotics and mortality risk. BMJ Open, 2, e000850.
Shader, R. I., & Greenblatt, D. J. (1993). Use of benzodiazepines in anxiety disorders. N Engl J Med, 328, 1398–1405.
Greenblatt, D. J., Harmatz, J. S., & Shader, R. I. (1991). Pharmacokinetics of benzodiazepines in elderly. Clin Pharmacokinet, 21, 167–177.
Olkkola, K. T., & Ahonen, J. (2008). Midazolam and CYP3A interactions. Clin Pharmacokinet, 47, 749–766.
Morin, C. M., & Benca, R. (2012). Chronic insomnia. Lancet, 379, 1129–1141.
Qaseem, A., Kansagara, D., Forciea, M. A., et al. (2016). Management of chronic insomnia. Ann Intern Med, 165, 125–133.
Wafford, K. A., & Ebert, B. (2008). Gabapentin and pregabalin pharmacology. CNS Drug Rev, 14, 61–75.
Wade, A. G., Ford, I., Crawford, G., et al. (2007). Efficacy of prolonged-release melatonin in elderly. Curr Med Res Opin, 23, 2597–2605.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Iga Rusin, Amadea Wrzesińska, Mateusz Korowacki, Michał Przybylski, Bartosz Świrad, Krystian Mączka , Karol Kazimierczak, Daniel Grobecki, Filip Kruczek, Jakub Dyczko
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
